Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
healthcare professional
|
| gptkbp:chemical_formula |
C6420 H9920 N1716 O1984 S44
|
| gptkbp:class |
immunomodulator
|
| gptkbp:clinical_trial |
gptkb:UNCOVER-1
gptkb:UNCOVER-2 gptkb:UNCOVER-3 Phase III |
| gptkbp:contraindication |
active infections
hypersensitivity to the drug |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:effective_date |
FDA approved
2016-03-22 |
| gptkbp:financial_stability |
24 months
|
| gptkbp:formulation |
auto-injector
pre-filled syringe |
| gptkbp:frequency |
once every 4 weeks after initial doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ixekizumab
|
| gptkbp:indication |
gptkb:ankylosing_spondylitis
active psoriatic arthritis moderate to severe plaque psoriasis |
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
signs of infection
blood cell counts |
| gptkbp:marketed_as |
gptkb:Taltz
|
| gptkbp:mechanism_of_action |
inhibits IL-17 A
|
| gptkbp:patient_population |
adults
children over 6 years |
| gptkbp:provides_guidance_on |
American Academy of Dermatology guidelines
European guidelines for psoriasis treatment |
| gptkbp:research_focus |
patient-reported outcomes
safety profile long-term efficacy comparative effectiveness |
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
fatigue
headache nausea allergic reactions injection site reactions thrombocytopenia gastrointestinal disorders upper respiratory infections neutropenia serious infections |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:IL-17_A
|
| gptkbp:used_for |
treatment of psoriasis
treatment of psoriatic arthritis |
| gptkbp:weight |
146 k Da
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|